The impact of COVID-19 pandemic on the rate of newly diagnosed gynecological and breast cancers: a tertiary center perspective.
Breast cancer
COVID-19
Carcinoma
Gynecology
Neoplasms
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
12
05
2021
accepted:
14
09
2021
pubmed:
25
9
2021
medline:
2
4
2022
entrez:
24
9
2021
Statut:
ppublish
Résumé
The aim of the present study was to assess the impact of postponed screening examinations and lockdown measures on gynecological and breast cancer diagnoses throughout the year 2020 in a gynecological oncological center in Austria. Data of 889 patients with either newly diagnosed gynecological or breast cancer between January 2019 and December 2020 were collected. Clinical parameters including symptoms, performance status, comorbidities and referral status were compared in patients, who were newly diagnosed with cancer in the period of the first lockdown from March 2020 to April 2020 and the second lockdown from November 2020 to December 2020 and compared to the same period in 2019. Our results showed a strong decline in newly diagnosed cancers during the lockdown periods: -45% in gynecological cancer and -52% in breast cancer compared to the same period in 2019. Compared to the analogue period of 2019, breast cancer patients reported significantly more tumor-associated symptoms (55% vs. 31%, p = 0.013) during and in between (48% vs. 32%, p = 0.022) the lockdowns. During the lockdown, periods in the group of breast cancer patients' tumor stage varied significantly compared to 2019 (T2-T4; p = 0.047). Both lockdowns led to a strong decrease in newly diagnosed gynecological and breast cancers. Treatment delays in potentially curable disease could lead to inferior clinical outcomes, with the risk of missing the optimal treatment window. As the COVID-19 pandemic will be a challenge for some time to come, new strategies in patient care are needed to optimize cancer screening and management during the pandemic.
Identifiants
pubmed: 34559295
doi: 10.1007/s00404-021-06259-5
pii: 10.1007/s00404-021-06259-5
pmc: PMC8460407
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
945-953Informations de copyright
© 2021. The Author(s).
Références
John Hopkins University and Medicine (2020) COVID-19 Map—Johns Hopkins Coronavirus Resource Center. 2020 [cited 26 Jan 2021]. https://coronavirus.jhu.edu/map.html .
Federal Ministry of Social Affairs, Healthcare and Consumer Protection, Republic of Austria (2020) Official COVID19 Dashboard (Public Information): hospitalisation [cited 26 Jan 2021]. https://info.gesundheitsministerium.at/dashboard_Hosp.html?l=de .
Tsibulak I, Reiser E, Bogner G, Petru E, Hell-Teutsch J, Reinthaller A et al (2020) Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective. Int J Gynecol Cancer 30(11):1667–1671
doi: 10.1136/ijgc-2020-001975
EPIC Health Research Network (EHRN) Preventive cancer screenings during COVID-19 pandemic (2020). Accessed 12 June 2020. https://ehrn.org/wp-content/uploads/Preventive-Cancer-Screenngs-during-COVID-19-Pandemic.pdf
Gorin SNS, Jimbo M, Heizelman R, Harmes KM, Harper DM (2021) The future of cancer screening after COVID-19 may be at home. Cancer 127(4):498–503. https://doi.org/10.1002/cncr.33274 (Epub 10 Nov 2020; PMID: 33170520)
doi: 10.1002/cncr.33274
pubmed: 33170520
Patt D, Gordan L, Diaz M, Okon T, Grady L, Harmison M et al (2020) Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform 4:1059–1071
doi: 10.1200/CCI.20.00134
Turnbull C (2021) Effect of COVID-19 on colorectal cancer care in England. Lancet Gastroenterol Hepatol S2468–1253(21):00017. https://doi.org/10.1016/S2468-1253(21)00017-0
doi: 10.1016/S2468-1253(21)00017-0
Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh QD (2021) Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.7600
doi: 10.1001/jamaoncol.2020.7600
pubmed: 33662110
pmcid: 7934079
Oldani C, Vanni G, Buonomo OC (2020) COVID-19 unintended effects on breast cancer in Italy after the great lockdown. Front Public Health 8:601748. https://doi.org/10.3389/fpubh.2020.601748
doi: 10.3389/fpubh.2020.601748
pubmed: 33425839
pmcid: 7786396
Kaufman HW, Chen Z, Niles J, Fesko Y (2020) Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw Open 3(8):e2017267. https://doi.org/10.1001/jamanetworkopen.2020.17267.)
doi: 10.1001/jamanetworkopen.2020.17267.)
pubmed: 32749465
pmcid: 7403918
Morais S, Antunes L, Rodrigues J, Fontes F, Bento MJ, Lunet N (2021) The impact of the coronavirus disease 2019 pandemic on the diagnosis and treatment of cancer in Northern Portugal. Eur J Cancer Prev. https://doi.org/10.1097/CEJ.0000000000000686
doi: 10.1097/CEJ.0000000000000686
pubmed: 34456263
pmcid: 8808756
Mancebo G, Solé-Sedeño JM, Membrive I, Taus A, Castells M, Serrano L et al (2020) Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19). Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2020-001942
doi: 10.1136/ijgc-2020-001942
pubmed: 33020205
Uwins C, Bhandoria GP, Shylasree TS, Butler-Manuel S, Ellis P, Chatterjee J et al (2020) COVID-19 and gynecological cancer: a review of the published guidelines. Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2020-001634
doi: 10.1136/ijgc-2020-001634
pubmed: 32576608
Hawkes D, Keung MHT, Huang Y, McDermott TL, Romano J, Saville M, Brotherton JML (2020) Self-collection for cervical screening programs: from research to reality. Cancers 12(4):1053. https://doi.org/10.3390/cancers12041053
doi: 10.3390/cancers12041053
pmcid: 7226191